Market Overview

Jazz Pharma Begins Trial of IV Administered Erwinaze

Related JAZZ
BMO Sees Jazz Pharma As 'A Rare Breed In Specialty Pharma'
Goldman Initiates Specialty Pharma At Neutral, Highlights 'A Confluence Of Concerns'
Jazz Pharmaceuticals Is One Of The Most Attractive Biotech Stocks (Seeking Alpha)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze^® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

Posted-In: News FDA


Related Articles (JAZZ)

View Comments and Join the Discussion!